For Immediate Release
Dr. Daniele Piomelli Appointed Editor-in-Chief of Cannabis and Cannabinoid Research
Contact: Kathryn Ryan
914-740-2250
kryan@liebertpub.com
New Rochelle, NY, July 30, 2015—Mary Ann Liebert, Inc., publishers is pleased to announce that Daniele Piomelli, PhD, PharmD, has been appointed Editor-in-Chief of Cannabis and Cannabinoid Research. Dr. Piomelli serves as Louise Turner Arnold Chair in Neurosciences and Professor of Anatomy and Neurobiology, Pharmacology, and Biological Chemistry at University of California, Irvine. He is also founding director of the unit of drug discovery and development (D3) at the Italian Institute of Technology in Genoa, Italy. We are pleased to welcome Dr. Piomelli and launch Cannabis and Cannabinoid Research with his expert guidance.
Dr. Piomelli earned his degree of Doctor of Pharmacy from University of Naples. He studied Pharmacology and Neuroscience with James H. Schwartz and Eric Kandel at Columbia University, and later with Paul Greengard at the Rockefeller University. Kandel and Greengard received the Nobel Prize in medicine in 2000. Dr. Piomelli has held faculty positions at the INSERM in Paris and at the Neurosciences Institute in La Jolla, CA with Nobel laureate Gerald Edelman.
Dr. Piomelli has made several contributions to the pharmacology of lipid-based signaling molecules. With his collaborators, he elucidated the biochemical pathways involved in the formation and deactivation of endocannabinoid substances – including anandamide and 2-AG – and uncovered various physiological functions served by these substances in the brain and in peripheral tissues. Additionally, his lab discovered the role of the lipid amides – oleoylethanolamide and palmitoylethanolamide – in the control of energy balance, inflammation, and pain, and identified their cellular receptors. Finally, Dr. Piomelli and his collaborators developed pharmacological agents that target various aspects of endocannabinoid and lipid amide signaling, which could be useful in the treatment of pain, anxiety disorders, addiction, and inflammation.
Dr. Piomelli is the author of more than 300 peer-reviewed articles, three full-length books, and 25 patents. He has received several awards and honors, including the Dargut and Milena Kemali Prize in Neuroscience and the National Alliance for Research on Depression and Schizophrenia (NARSAD) Outstanding Investigator Award.
“Researchers who work on the many different aspects covered by cannabinoid biology and medicine previously did not have a journal that they can call their own,” says Dr. Piomelli. “Cannabis and Cannabinoid Research will be that journal.”
Dr. Piomelli will take editorship immediately and begin developing the Journal to launch in Fall of 2015.
For information on manuscript submission, please visit the Cannabis and Cannabinoid Research website.
About the Journal
Cannabis and Cannabinoid Research is the only peer-reviewed open access journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the endocannabinoids system. Led by Editor-in-Chief Daniele Piomelli, PhD, PharmD, the Journal publishes a broad range of human and animal studies including basic and translational research; clinical studies; behavioral, social, and epidemiological issues; and ethical, legal, and regulatory controversies. Complete information is available on the Cannabis and Cannabinoid Research website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Medicinal Food, The Journal of Alternative and Complementary Medicine, and Journal of Child and Adolescent Psychopharmacology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.